Tenon Medical, Inc. (TNON) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The company demonstrated strong financial performance with a significant increase in both quarterly and annual revenue, driven by new product adoption. Gross margins improved, and net losses decreased, indicating operational efficiency. Despite competitive pressures, the strategic expansion of the product portfolio and positive reception of new launches like SImmetry+ suggest potential growth. The Q&A revealed management's optimism about revenue growth, despite vague guidance. The decrease in cash reserves is a concern but offset by strategic investments. Overall, the positive financial results and optimistic outlook suggest a positive stock price movement.

Key Financial Performance

Full Year Revenue $3.9 million, a 20% increase compared to 2024. The increase was driven by growth in surgical procedures across both the Catamaran and SImmetry+ platforms, led by new physician users.

Fourth Quarter Revenue $1.5 million, representing a 92% increase over the prior year period. The increase was primarily due to growth in surgical procedure volume across both the Catamaran and SImmetry+ platforms, driven by new physician adoption.

Gross Profit (Fourth Quarter) $1 million or 69% of revenue, an increase of 188% compared to $0.4 million or 46% of revenue in the prior year quarter. The improvement was driven by higher revenue and further absorption of fixed costs within cost of goods sold.

Gross Profit (Full Year) $2.4 million or 60% of revenue, a 38% increase compared to $1.7 million or 52% of revenue in the previous year's period. The improvement was driven by higher revenue and further absorption of fixed costs within cost of goods sold.

Operating Expenses (Fourth Quarter) $3.9 million, up from $3.5 million in the prior year quarter. The increase was primarily due to higher variable expenses within sales and marketing, driven by increased revenue in the period.

Operating Expenses (Full Year) $15.2 million, compared to $15.5 million in the prior year period. The decrease was due to reduced general and administrative expenses, partially offset by increased sales and marketing investments to support increased sales and continued commercial expansion.

Net Loss (Fourth Quarter) $2.8 million or $0.29 per share, compared to a net loss of $3.1 million or $0.98 per share in the fourth quarter of 2024. The improvement was largely driven by increased revenue as well as reduced general and administrative expenses.

Net Loss (Full Year) $12.6 million or $1.70 per share, compared to $13.7 million or $11.26 per share in the same year ago period. The improvement was largely driven by increased revenue as well as reduced general and administrative expenses.

Cash and Cash Equivalents $3.8 million as of December 31, 2025, compared to $6.5 million as of December 31, 2024. The decrease reflects operational expenses and investments made during the year.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

FDA 510(k) clearance for SImmetry+ SI-Joint Fusion System: Received clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding the portfolio to include a complementary lateral approach alongside Catamaran. Early clinical cases were successfully initiated and completed, validating readiness for broader market adoption.

Revenue Growth: Achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024. Fourth-quarter revenue was $1.5 million, a 92% increase over the prior year period, driven by growth in surgical procedures and new physician users.

Market Penetration: Expanded market reach through increased physician engagement and training sessions, hosting 24 physicians in targeted training during Q4.

Operational Efficiencies: Reduced cost of sales through improved operational efficiencies, better field productivity, and greater leverage within the commercial infrastructure. Gross margin improved to 69% in Q4 2025 from 46% in Q4 2024.

Financial Position: Strengthened financial position with $2.85 million PIPE financing and $4.3 million private placement of senior convertible notes, providing flexibility for commercial expansion and product rollouts.

Intellectual Property Expansion: Expanded intellectual property portfolio to 29 issued U.S. patents, 9 international patents, and 31 pending applications, reinforcing platform defensibility.

Strategic Growth Initiatives: Focused on optimizing cost structure, scaling operations, and refining go-to-market strategy to accelerate revenue growth and deepen market penetration.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Revenue Growth Dependency: The company's revenue growth is heavily dependent on the adoption of its surgical platforms (Catamaran and SImmetry+). Any slowdown in physician adoption or market acceptance could adversely impact financial performance.

Financial Sustainability: Despite revenue growth, the company reported a net loss of $12.6 million for 2025. Continued losses could strain financial resources and limit operational flexibility.

Cash Reserves: The company ended the year with $3.8 million in cash, down from $6.5 million in 2024. Although additional financing was secured, reliance on external funding could pose risks if future capital is not readily available.

Regulatory and Clinical Risks: The company relies on FDA clearances and clinical validations for its products. Any delays or failures in regulatory approvals or clinical studies could hinder product rollouts and market expansion.

Operational Efficiency: While operational efficiencies have improved, the company faces challenges in maintaining cost reductions and scaling operations effectively to support growth.

Market Competition: The company operates in a competitive medical device market. Failure to differentiate its products or respond to competitive pressures could impact market share and revenue.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Revenue Growth: The company expects the revenue growth momentum observed in the second half of 2025 to continue throughout 2026, driven by increased surgical procedure volumes and new physician adoption.

Gross Margin Improvement: Gross margin is expected to continue improving with further revenue growth, supported by higher revenue and better absorption of fixed costs within the cost of goods sold.

Product Portfolio Expansion: The recent FDA 510(k) clearance of the SImmetry+ SI-Joint Fusion System is expected to drive broader commercial uptake and deepen physician engagement, leveraging regulatory and market momentum.

Financial Position: The company has strengthened its financial position with a $4.3 million private placement of senior convertible notes, providing additional runway to fund commercial and clinical priorities deep into 2026.

Operational Efficiency: The company plans to optimize its cost structure and scale operations to extend market reach more efficiently, aiming to accelerate revenue growth and deliver sustained value in the quarters ahead.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:How representative is the Q4 operating expense rate of $3.9 million for 2026?

A:Kevin Williamson stated that the Q4 rate is a good baseline for 2026. He explained that higher integration and deal-related costs in Q3 fell out in Q4, and higher variable expenses due to increased revenue offset some of the costs. This resulted in a better run rate for Q4 moving forward.

Q:How should we think about the $6 million annualized revenue run rate for 2026, especially for Q1?

A:Steven Foster mentioned that while they do not provide future projections, they are excited about adoption momentum, record metrics, and a strong pipeline. Kevin Williamson added that the momentum from Q4, the commercialization of SImmetry+, and new product launches in 2026 will drive revenue growth, with Q4 likely being the highest revenue quarter.

Q:What are the key drivers for revenue growth in 2026?

A:Steven Foster highlighted the multiproduct portfolio, including Catamaran SE, SImmetry+, and upcoming product launches. He emphasized commercial expansion and execution, backed by data and diverse solutions for sacropelvic challenges. Kevin Williamson agreed with these points.

Q:How has the launch of SImmetry+ impacted physician adoption and access to medical centers?

A:Steven Foster explained that the broader portfolio, including SImmetry+, provides multiple solutions for physicians, addressing various approaches and patient needs. SImmetry+ has been well-received for its 3D-printed technology and efficient instrument set. The phased launch will include additional features in 2026.

Q:How does the company balance training and selling for new products, and is the portfolio complete?

A:Steven Foster stated that they focus on refining existing technology to make it 'sticky' while developing new technologies. He mentioned upcoming FDA submissions for new products that will provide more flexibility for physicians. The portfolio addresses primary cases, revision cases, and adjuncts to complex spine procedures.

Q:Review of Unclear Management Responses

A:Management avoided giving direct revenue projections for 2026, using vague language about adoption momentum, record metrics, and a strong pipeline instead of providing specific figures or detailed guidance.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

TNON Transcript

Central Asia Metals plc (CAMLF) Q4 2025 Earnings Call Transcript

Unknown3-19

The earnings call highlighted several concerns: a significant impairment charge, increased costs, and negative EPS. Although revenue grew, it was offset by rising costs and a substantial impairment. The Q&A revealed vague responses on cost management and future projects, adding uncertainty. The reinstated dividend policy is a positive, but overall, the financial health and guidance raise concerns. Given these factors, the sentiment is negative, suggesting a potential stock price decline of -2% to -8% in the short term.

Tenon Medical, Inc. (TNON) Q4 2025 Earnings Call Transcript

Positive3-19

Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript

Positive11-13

The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.

Tenon Medical, Inc. (TNON) Q2 2025 Earnings Call Transcript

Unknown8-13

Despite some positive developments like the SiVantage acquisition and the upcoming Symmetry Plus launch, the company's financial performance shows significant declines in revenue, gross profit, and net loss compared to the previous year. Additionally, management's vague responses about the merger's financial impact and the uncertain timeline for Symmetry Plus launch contribute to negative sentiment. The economic uncertainty and market adoption risks further add to the concerns. The lack of strong guidance or shareholder return plans also supports a negative outlook for the stock price in the short term.

TNON Report

Tenon Medical, Inc. S-1

S-1

2024-08-14

Tenon Medical, Inc. 10-Q

10-Q

2024-08-13

Tenon Medical, Inc. 10-Q

10-Q

2024-05-15

Tenon Medical, Inc. S-1

S-1

2024-05-10

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.